BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 33457076)

  • 1. Expression of placenta-specific 1 and its potential for eliciting anti-tumor helper T-cell responses in head and neck squamous cell carcinoma.
    Hayashi R; Nagato T; Kumai T; Ohara K; Ohara M; Ohkuri T; Hirata-Nozaki Y; Harabuchi S; Kosaka A; Nagata M; Yajima Y; Yasuda S; Oikawa K; Kono M; Kishibe K; Takahara M; Katada A; Hayashi T; Celis E; Harabuchi Y; Kobayashi H
    Oncoimmunology; 2020 Dec; 10(1):1856545. PubMed ID: 33457076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy.
    Kumai T; Matsuda Y; Oikawa K; Aoki N; Kimura S; Harabuchi Y; Celis E; Kobayashi H
    Br J Cancer; 2013 Oct; 109(8):2155-66. PubMed ID: 24045666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
    Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
    J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of two new HLA-A*0201-restricted cytotoxic T lymphocyte epitopes from colorectal carcinoma-associated antigen PLAC1/CP1.
    Liu F; Zhang H; Shen D; Wang S; Ye Y; Chen H; Pang X; Song Q; He P
    J Gastroenterol; 2014 Mar; 49(3):419-26. PubMed ID: 23604623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MAGE-A3 and MAGE-A4 specific CD4(+) T cells in head and neck cancer patients: detection of naturally acquired responses and identification of new epitopes.
    Cesson V; Rivals JP; Escher A; Piotet E; Thielemans K; Posevitz V; Dojcinovic D; Monnier P; Speiser D; Bron L; Romero P
    Cancer Immunol Immunother; 2011 Jan; 60(1):23-35. PubMed ID: 20857101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a novel HLA-A2-restricted cytotoxic T lymphocyte epitope from cancer-testis antigen PLAC1 in breast cancer.
    Liu W; Zhai M; Wu Z; Qi Y; Wu Y; Dai C; Sun M; Li L; Gao Y
    Amino Acids; 2012 Jun; 42(6):2257-65. PubMed ID: 21710262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer immunotherapy using novel tumor-associated antigenic peptides identified by genome-wide cDNA microarray analyses.
    Nishimura Y; Tomita Y; Yuno A; Yoshitake Y; Shinohara M
    Cancer Sci; 2015 May; 106(5):505-11. PubMed ID: 25726868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen.
    Kobayashi H; Omiya R; Ruiz M; Huarte E; Sarobe P; Lasarte JJ; Herraiz M; Sangro B; Prieto J; Borras-Cuesta F; Celis E
    Clin Cancer Res; 2002 Oct; 8(10):3219-25. PubMed ID: 12374692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recognition of prostate and melanoma tumor cells by six-transmembrane epithelial antigen of prostate-specific helper T lymphocytes in a human leukocyte antigen class II-restricted manner.
    Kobayashi H; Nagato T; Sato K; Aoki N; Kimura S; Murakami M; Iizuka H; Azumi M; Kakizaki H; Tateno M; Celis E
    Cancer Res; 2007 Jun; 67(11):5498-504. PubMed ID: 17545632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recognition of prostate and breast tumor cells by helper T lymphocytes specific for a prostate and breast tumor-associated antigen, TARP.
    Kobayashi H; Nagato T; Oikawa K; Sato K; Kimura S; Aoki N; Omiya R; Tateno M; Celis E
    Clin Cancer Res; 2005 May; 11(10):3869-78. PubMed ID: 15897588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma.
    Kono M; Komatsuda H; Yamaki H; Kumai T; Hayashi R; Wakisaka R; Nagato T; Ohkuri T; Kosaka A; Ohara K; Kishibe K; Takahara M; Katada A; Hayashi T; Kobayashi H; Harabuchi Y
    Oncoimmunology; 2022; 11(1):2021619. PubMed ID: 35003900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitogen-activated protein kinase inhibition augments the T cell response against HOXB7-expressing tumor through human leukocyte antigen upregulation.
    Komatsuda H; Wakisaka R; Kono M; Kumai T; Hayashi R; Yamaki H; Sato R; Nagato T; Ohkuri T; Kosaka A; Ohara K; Takahara M; Katada A; Kobayashi H
    Cancer Sci; 2023 Feb; 114(2):399-409. PubMed ID: 36285482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK/T cell lymphoma.
    Kumai T; Matsuda Y; Ohkuri T; Oikawa K; Ishibashi K; Aoki N; Kimura S; Harabuchi Y; Celis E; Kobayashi H
    Oncoimmunology; 2015 Feb; 4(2):e976077. PubMed ID: 25949874
    [No Abstract]   [Full Text] [Related]  

  • 14. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor.
    Tomita Y; Yuno A; Tsukamoto H; Senju S; Kuroda Y; Hirayama M; Irie A; Kawahara K; Yatsuda J; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y
    Clin Cancer Res; 2013 Aug; 19(16):4508-20. PubMed ID: 23714729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen.
    Kobayashi H; Wood M; Song Y; Appella E; Celis E
    Cancer Res; 2000 Sep; 60(18):5228-36. PubMed ID: 11016652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PLAC1: biology and potential application in cancer immunotherapy.
    Mahmoudian J; Ghods R; Nazari M; Jeddi-Tehrani M; Ghahremani MH; Ghaffari-Tabrizi-Wizsy N; Ostad SN; Zarnani AH
    Cancer Immunol Immunother; 2019 Jul; 68(7):1039-1058. PubMed ID: 31165204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactive CD4+ T cells.
    Mandic M; Almunia C; Vicel S; Gillet D; Janjic B; Coval K; Maillere B; Kirkwood JM; Zarour HM
    Cancer Res; 2003 Oct; 63(19):6506-15. PubMed ID: 14559844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of promiscuous HLA-DR-restricted CD4⁺ T-cell epitopes on the cancer-testis antigen HCA587.
    Wen W; Zhang L; Peng J; Chen J; Hao J; Li X; Qian X; Zeng P; Zhang Y; Yin Y
    Cancer Sci; 2011 Aug; 102(8):1455-61. PubMed ID: 21595801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenotype of p53 wild-type epitope-specific T cells in the circulation of patients with head and neck cancer.
    Albers AE; Qian X; Kaufmann AM; Mytilineos D; Ferris RL; Hoffmann TK; DeLeo AB
    Sci Rep; 2018 Jul; 8(1):10716. PubMed ID: 30013227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In silico Evaluation of PLAC1-fliC As a Chimeric Vaccine against Breast Cancer.
    Taheri-Anganeh M; Amiri A; Movahedpour A; Khatami SH; Ghasemi Y; Savardashtaki A; Mostafavi-Pour Z
    Iran Biomed J; 2020 May; 24(3):173-82. PubMed ID: 31952435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.